Results 71 to 80 of about 189,634 (339)

Clinical variability of equine asthma phenotypes and analysis of diagnostic steps in phenotype differentiation

open access: yesActa Veterinaria Scandinavica
Background Equine asthma is a common, non-infectious, chronic lung disease that affects up to 80% of the horse population. Strict phenotyping and identification of subclinically asthmatic horses can be challenging.
Lia Kristin Meiseberg   +3 more
doaj   +1 more source

Early cystic fibrosis lung disease detected by bronchoalveolar lavage and lung clearance index.

open access: yesAmerican Journal of Respiratory and Critical Care Medicine, 2012
RATIONALE Unrecognized airway infection and inflammation in young children with cystic fibrosis (CF) may lead to irreversible lung disease; therefore early detection and treatment is highly desirable.
Y. Belessis   +10 more
semanticscholar   +1 more source

Deficiency of DEK proto‐oncogene alleviates allergic rhinitis by inhibiting RhoA/Ezrin‐mediated mitochondrial fission

open access: yesAnimal Models and Experimental Medicine, EarlyView.
Schematic diagram of the mechanism of DEK regulating RhoA activation Ezrin. Upon house dust mite (HDM) stimulation, HDM‐specific immunoglobulin E (IgE) and inflammatory factors such as interleukin 4 (IL‐4), IL‐5, IL‐13, and eosinophils increased in the nasal mucosa.
Longzhu Dai   +8 more
wiley   +1 more source

Clinical Aspects and Evolution under Current Treatments on Pulmonary Alveolar Phospholipoproteinosis Patients

open access: yesFolia Medica, 2019
A 34-year-old female smoker (4 packs a year), with the following symptoms: dry cough, moderate dyspnea, fatigue, night sweats and no exposure to respiratory poisoning or contact with tuberculosis.
Muntean Petru-Emil
doaj   +1 more source

Long‐Circulating Nanobody Confers Durable Prophylaxis against Severe Acute Respiratory Syndrome Coronavirus 2 Omicron Infection

open access: yesAdvanced NanoBiomed Research, EarlyView.
This study explores Fc engineering to extend nanobody half‐lives in vivo. Herein, it is demonstrated that the circulation half‐life of Nanosota‐3A‐Fc, a novel nanobody with potent neutralizing activity against SARS‐CoV‐2 Omicron BA.1 variant, can be greatly prolonged by introducing M252Y/S254T/T256E (YTE) substitutions in the IgG1 Fc domain, which ...
Geetha Jyothi Vaskuri   +9 more
wiley   +1 more source

Clinical Factors Associated With Pneumocystis Pneumonia Despite Its Primary Prophylaxis: When to Stop Prophylaxis?

open access: yesArthritis &Rheumatology, EarlyView.
Objective Although previous studies show that primary prophylaxis against Pneumocystis jirovecii pneumonia (PJP) is effective in patients with rheumatic diseases receiving immunosuppressive treatment, there is limited evidence regarding the optimal timing for prophylaxis withdrawal.
Ju Yeon Kim   +5 more
wiley   +1 more source

Antiphospholipid Syndrome: An Antibody‐Mediated Disease With Emerging Therapeutic Opportunities

open access: yesArthritis &Rheumatology, EarlyView.
Antiphospholipid syndrome (APS) is an autoimmune thromboinflammatory disease characterized by vascular thrombosis, pregnancy morbidity, and other manifestations driven by antiphospholipid autoantibodies. In this review, we present a clinical case that illustrates some diagnostic and therapeutic challenges in managing severe, relapsing APS ...
Thalia G. Newman, Jason S. Knight
wiley   +1 more source

Bronchoalveolar lavage galactomannan for the diagnosis of chronic pulmonary aspergillosis.

open access: yesMedical Mycology, 2012
Diagnosing chronic pulmonary aspergillosis (CPA) is complicated, and there are limited data available regarding the identification of galactomannan (GM) in clinical specimens to assist the detection of this infection.
K. Izumikawa   +16 more
semanticscholar   +1 more source

B cells and systemic sclerosis interstitial lung disease

open access: yesArthritis &Rheumatology, Accepted Article.
Interstitial lung disease is an important complication of systemic sclerosis (SSc‐ILD) with high mortality and morbidity. Recent clinical studies in SSc‐ILD have led to FDA‐approved therapies in SSc‐ILD. Importantly, evidence from these studies has been extrapolated to guide management of interstitial lung diseases of other systemic autoimmune ...
Nina Goldman   +2 more
wiley   +1 more source

Home - About - Disclaimer - Privacy